ATC Group: A02BC06 Dexlansoprazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BC06 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A02 Drugs for acid related disorders
3 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4 A02BC Proton pump inhibitors
5 A02BC06 Dexlansoprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg

Active ingredients in A02BC06

Active Ingredient Description
Dexlansoprazole

Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell.

Related product monographs

Title Information Source Document Type  
DEXILANT Delayed-release capsules FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Ecuador (EC)

Germany (DE)

Hong Kong (HK)

Israel (IL)

Lithuania (LT)

Mexico (MX)

Poland (PL)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.